• Profile
Close

Combination of intravitreal bevacizumab and erythropoietin vs intravitreal bevacizumab alone for refractory diabetic macular edema: A randomized double-blind clinical trial

Graefe's Archive for Clinical and Experimental Ophthalmology Nov 08, 2019

Entezari M, Flavarjani ZK, Ramezani A, et al. - Researchers examined the efficacy of three intravitreal bevacizumab (IVB) injections alone or in combination with intravitreal erythropoietin (EPO) for the treatment of refractory diabetic macular edema (DME). They conducted a randomized double-blind clinical trial enrolling 48 eyes of 34 diabetic patients with refractory DME. Either 3 monthly injections of 0.05 cc (1.25 mg) IVB plus 0.05 cc (1,000 unit) EPO or 0.05 cc (1.25 mg) IVB alone was administered in the eyes. Both groups exhibited insignificant mean best-corrected visual acuity changes up to 4 and 6 months. Outcomes revealed no additional effect of intravitreal erythropoietin to IVB in the treatment of refractory DME in the short term.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay